Are all gonadotrophin‐releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review

To review direct comparative studies of the gonadotrophin‐releasing hormone (GnRH) agonists goserelin, triptorelin, and leuprorelin for the treatment of prostate cancer, and identify whether there are meaningful clinical differences between these agents. In June 2017, the following searches were per...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BJU international 2018-09, Vol.122 (3), p.371-383
Hauptverfasser:	Bolton, Eva M., Lynch, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	androgen‐deprivation therapy Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Castration Clinical trials Gonadotropin-releasing hormone Gonadotropin-Releasing Hormone - agonists goserelin Goserelin - adverse effects Goserelin - therapeutic use Humans Leuprolide - adverse effects Leuprolide - therapeutic use leuprorelin Male Patients PCSM Pituitary (anterior) Prostate cancer ProstateCancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Survival Rate Testosterone Testosterone - blood Treatment Outcome triptorelin Triptorelin Pamoate - adverse effects Triptorelin Pamoate - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!